Kerry Group (KYGA)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 99.00 |
|---|---|
| 52-week range | 64.35 – 100.00 |
| Return, 1 month / 3 months | +17.6% / +22.6% |
| Return, 1 year / 3 years | +19.3% / +42.6% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 36.5% |
| Worst drawdown (1 year) | -23.5% |
| Average daily value traded | 6.27M EUR |
| Dividend yield | 1.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kerry Group is an Irish food and nutrition company based in Tralee, County Kerry. It supplies taste and nutrition ingredients and solutions to food, beverage and pharmaceutical manufacturers around the world, helping them develop products with particular flavours, textures and nutritional profiles. The company also makes consumer foods, including dairy products, cheeses and chilled convenience foods sold under its own brands in Ireland and the United Kingdom. Its customers range from large international food and drink producers to retail shoppers.
The shares are listed on the London Exchange in UK under the code KYGA, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kerry Group (KYGA) trades on the London Exchange in UK. It last closed at EUR 99.00 on 23 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 564 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 19.3% and over the last three months it rose 22.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 28.5% | ||
| From 52-week high | 0.0% | ||
| Momentum | 77 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 22.6% | ||
| 6-month return | 45.1% | ||
| 12-month return, skipping the last month | 1.4% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 36.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.5% | ||
| Liquidity | 70 · Fair | Moderate trading activity. | |
| Average daily value traded | 6.27M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.5% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.2% |
|---|---|
| 1 month | +17.6% |
| 3 months | +22.6% |
| 6 months | +45.1% |
| 1 year | +19.3% |
| 3 years | +42.6% |
| 5 years | −7.9% |
Signals
| 50-day / 200-day average | 86.25 / 77.03 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.58 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Oct 2026 | EUR 0.4620 |
| 9 Apr 2026 | EUR 0.9800 |
| 9 Oct 2025 | EUR 0.4200 |
| 10 Apr 2025 | EUR 0.8900 |
| 10 Oct 2024 | EUR 0.3810 |
| 11 Apr 2024 | EUR 0.8080 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.